Dexcom (DXCM)Director sold ~$130K

~$130K

Approx. value · 1,550 sh @ $84.02

36K

Holds after · shares reported

Traded

Sep 14, 2026

Filed

Sep 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 15, 2026InsiderOfficer sold ~$127K of DXCM shares in the open market
2. Jul 20, 2026InsiderChair sold ~$2.04M of DXCM shares in the open market
3. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
4. Jul 31, 2026InsiderDirector sold ~$160K of DXCM shares in the open market
5. Aug 3, 2026InsiderDirector sold ~$171K of DXCM shares in the open market
6. Aug 11, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
7. Aug 12, 2026InsiderDirector sold ~$89K of DXCM shares in the open market
8. Aug 14, 2026InsiderOfficer sold ~$156K of DXCM shares in the open market
9. Aug 20, 2026Insider · 1 personInsiders: 3 sales (~$2.4M)
10. Aug 27, 2026InsiderOfficer sold ~$227K of DXCM shares in the open market
11. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.”
12. Sep 10, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.”
13. Sep 10, 2026InsiderOfficer sold ~$303K of DXCM shares in the open market
14. Sep 14, 2026 · this disclosureInsiderDirector sold ~$130K of DXCM shares in the open market

What came next

1. Sep 15, 2026Insider · 2 peopleInsiders: 2 sales (~$692K)
2. Sep 28, 2026InsiderOfficer sold ~$221K of DXCM shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Nicholas Augustinos, Director

• SEC Form 4 at Dexcom (DXCM)Sep 16, 2026
• SEC Form 4 at Dexcom (DXCM)Jun 17, 2025
• SEC Form 4 at Dexcom (DXCM)Jun 17, 2025

The full history of Nicholas Augustinos, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dexcom

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 144Sep 15, 2026
• SEC Form 144Sep 15, 2026

Everything OQRO holds on this company is on its DXCM page.